Venetoclax Tablets
Venetoclax Tablets
for oral use Initial U.S. Approval: 2016
Venetoclax tablets is “used to treat Chronic Lymphocytic Leukemia (CLL) or in combination with azacitidine or low dose cytarabine for untreated Acute Myeloid Leukemia (AML)“. VENCLEXTA tablets is a “prescription medicine”. It is available in “form and strength” Tablets: 10 mg, 50 mg, 100 mg. VENCLEXTA for injection can be obtained in India upon request.
To inquire about the VENCLEXTA (venetoclax tablets) “offer price in India”, “shipping process”, and the “estimated time of availability in India”, please get in touch at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj). with the IPN Delhi healthcare team for further discussion.”
Facts about your medicine
Name: Venclyxto
Active substance: Venetoclax
Therapeutic area: Leukemia, Lymphocytic, Chronic, B-Cell
Marketing Authorisation: 04/12/2016.
AUTHORISED: This medicine is authorised for use in the European Union.
Medicine Approved By-European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Pharmaceuticals and Medical Devices Agency (PMDA), Therapeutic Goods Administration (TGA), Medsafe (NZ)
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)
Contact Info
CORPORATE OFFICE:
Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.
MOBILE / PHONE NUMBER:
M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398
EMAIL ID:
info@indianpharmanetwork.co.in
FAX NUMBER:
+91-11-26532129
Query For Venetoclax Tablets
Know about product usage and updates
Venetoclax, sold under the brand names Venclexta and Venclyxto, is a medication used to treat adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or acute myeloid leukemia (AML).
FDA grants regular approval to venetoclax in combination for untreated acute myeloid leukemia.
On October 16, 2020, the Food and Drug Administration granted regular approval to venetoclax (VENCLEXTA ®, AbbVie Inc. and Genentech Inc.) in combination with azacitidine, decitabine, or low-dose cytarabine (LDAC) for newly-diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities precluding intensive induction chemotherapy.
Who is the supplier of Specialty drug in India?
Indian Pharma Network (IPN) Legitimate consultant and facilitator for Specialty drugs in India. IPN, Delhi can assist you in connecting with prospective distributors, wholesalers, suppliers, and dealers of VENCLEXTA (venetoclax tablets). IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.
VENCLEXTA (venetoclax) tablets, for oral use Initial U.S. Approval: 2016
Related posts for product review usage
Related products
Indian Pharma Network (IPN), New Delhi. India
Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa
Mobile / WhatsApp / Phone
M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398
Free Customer Support
info@indianpharmanetwork.co.in
urgent@indianpharmanetwork.co.in